BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 33264276)

  • 1. A Retrospective Study on the Effects of Convalescent Plasma Therapy in 24 Patients Diagnosed with COVID-19 Pneumonia in February and March 2020 at 2 Centers in Wuhan, China.
    Huang S; Shen C; Xia C; Huang X; Fu Y; Tian L
    Med Sci Monit; 2020 Dec; 26():e928755. PubMed ID: 33264276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
    Li L; Zhang W; Hu Y; Tong X; Zheng S; Yang J; Kong Y; Ren L; Wei Q; Mei H; Hu C; Tao C; Yang R; Wang J; Yu Y; Guo Y; Wu X; Xu Z; Zeng L; Xiong N; Chen L; Wang J; Man N; Liu Y; Xu H; Deng E; Zhang X; Li C; Wang C; Su S; Zhang L; Wang J; Wu Y; Liu Z
    JAMA; 2020 Aug; 324(5):460-470. PubMed ID: 32492084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].
    Chen S; Lu C; Li P; Wang L; Wang H; Yang Q; Chen-Li Y; Li J; Ma H; Sang Q; Xu L; Li J; Zhang Y; Kang Y; Xing L; Zhang G
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Nov; 32(11):1293-1298. PubMed ID: 33463485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of transfusion convalescent recovery plasma in patients with coronavirus disease 2019.
    Xiao K; Lin Y; Fan Z; Wen Y; Huang H; Wang M; Ren D; Wu C; Liu W; Zhang Z; Li G; LE A
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):565-570. PubMed ID: 32879108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study.
    Wu Y; Hong K; Ruan L; Yang X; Zhang J; Xu J; Pan S; Ren L; Chen L; Huang C; Shang Y
    Virol Sin; 2020 Dec; 35(6):768-775. PubMed ID: 32865701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
    Ye M; Fu D; Ren Y; Wang F; Wang D; Zhang F; Xia X; Lv T
    J Med Virol; 2020 Oct; 92(10):1890-1901. PubMed ID: 32293713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
    Simonovich VA; Burgos Pratx LD; Scibona P; Beruto MV; Vallone MG; Vázquez C; Savoy N; Giunta DH; Pérez LG; Sánchez MDL; Gamarnik AV; Ojeda DS; Santoro DM; Camino PJ; Antelo S; Rainero K; Vidiella GP; Miyazaki EA; Cornistein W; Trabadelo OA; Ross FM; Spotti M; Funtowicz G; Scordo WE; Losso MH; Ferniot I; Pardo PE; Rodriguez E; Rucci P; Pasquali J; Fuentes NA; Esperatti M; Speroni GA; Nannini EC; Matteaccio A; Michelangelo HG; Follmann D; Lane HC; Belloso WH;
    N Engl J Med; 2021 Feb; 384(7):619-629. PubMed ID: 33232588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No SARS-CoV-2 RNA detected in the convalescent plasma of COVID-19 patients with different disease severity.
    Nomoto H; Kutsuna S; Okuma K; Kuramitsu M; Tezuka K; Ikebe E; Saito S; Kinoshita N; Terada M; Endo M; Suzuki T; Miyazato Y; Nakamoto T; Inada M; Hamaguchi I; Ohmagari N
    J Infect Chemother; 2021 Apr; 27(4):653-655. PubMed ID: 33487533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.
    Omrani AS; Zaqout A; Baiou A; Daghfal J; Elkum N; Alattar RA; Bakdach D; Abusriwil H; Mostafa AM; Alhariri B; Ambra N; Khatib M; Eldeeb AM; Merenkov Z; Fawzi Z; Hmissi SM; Hssain AA; Coyle PV; Alsoub H; Almaslamani MA; Alkhal A
    J Med Virol; 2021 Mar; 93(3):1678-1686. PubMed ID: 32965715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors.
    Ikegami S; Benirschke R; Flanagan T; Tanna N; Klein T; Elue R; Debosz P; Mallek J; Wright G; Guariglia P; Kang J; Gniadek TJ
    Transfusion; 2020 Dec; 60(12):2962-2968. PubMed ID: 32840002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 19. [Transfusion of convalescent plasma from patients with COVID -19].
    Galván CA; Toribio-Dionicio C; Álvarez-Ángeles M; Alama-Bazán O; Sánchez-Ramírez L
    Rev Peru Med Exp Salud Publica; 2020; 37(4):746-754. PubMed ID: 33566918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19.
    Raadsen MP; Gharbharan A; Jordans CCE; Mykytyn AZ; Lamers MM; van den Doel PB; Endeman H; van den Akker JPC; GeurtsvanKessel CH; Koopmans MPG; Rokx C; Goeijenbier M; van Gorp ECM; Rijnders BJA; Haagmans BL
    J Clin Immunol; 2022 Feb; 42(2):232-239. PubMed ID: 34767118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.